je.st
news
Tag: valeant
Valeant senior executives scored US$123 million compensation in 2014
2015-04-18 03:01:38| Biotech - Topix.net
The top five executives at Valeant Pharmaceuticals shared nearly US$123 million in compensation last year, up from US$23.8 million in 2013. Chairman and CEO Michael Pearson, who owns three per cent of the company with some 10 million shares, took the lowest compensation at US$10.28 million, while executive vice-president Ari Kellen topped the list at US$50.6 million, according to the company's proxy circular.
Tags: million
senior
compensation
scored
Valeant victorious in battle for Salix, gets majority of drug maker's stock
2015-04-01 15:20:42| Biotech - Topix.net
Valeant Pharmaceuticals International Inc. says its US$11.1-billion friendly takeover bid for Salix Pharmaceuticals, Ltd. was successful, with about three-quarters of all Salix shares tendered by the deadline early Wednesday. Valeant's offer of US$173 in cash per Salix share defeated a rival bid from Dublin-based Endo International, which had offered a combination of stock and cash valued at about US$175 per share.
Tags: stock
drug
majority
battle
Valeant boosts offer for Salix Pharma to about $11.11B
2015-03-16 14:06:50| Biotech - Topix.net
Valeant is raising its offer for Salix Pharmaceuticals to about $11.11 billion, heating up a bidding fight for the company. The Canadian drug maker's new bid is for $173 per Salix share, a 2 percent premium over Friday closing price of $169.40.
Tags: offer
pharma
boosts
salix
Fight for Salix Gets Hot; Valeant Ups Bid to About $11.11B
2015-03-16 14:06:49| Biotech - Topix.net
Valeant turned up the heat in its bidding fight for Salix Pharmaceuticals on Monday, raising its offer to about $11.11 billion in cash. The Canadian drugmaker now says it will pay $173 per Salix share, a 2 percent premium over Friday's closing price of $169.40.
Exclusive: Ackman's Pershing Square makes $3.3 billion bet on Valeant
2015-03-09 20:52:30| Biotech - Topix.net
Hedge fund mogul William Ackman has purchased a $3.3 billion stake in Valeant Pharmaceuticals International , making his firm the drug company's fifth-largest stakeholder, a source familiar with the matter said on Monday. Ackman's $20 billion Pershing Square Capital Management began building up the 5 percent stake in the Canadian drug maker this year, only months after his vocal effort to help Valeant buy Botox-maker Allergan failed.
Tags: makes
square
exclusive
billion
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »